Pricing Log in Create free account
Friday 6 November 2026 Export TMO’s income statement to Excel — free account

Thermo Fisher Scientific Inc.

TMO Healthcare Diagnostics & Research

Thermo Fisher Scientific Inc.’s revenue for fiscal 2025 (year ended December 2025) was $44.6 billion, up 3.91% from fiscal 2024.

Revenue
+9.13%
EPS
+8.64%
Free cash flow
+15.0%
Total debt
+22.8%

Quarter to September 2026, against a year earlier

689.49 12.55 +1.85%
Market cap
$250.8B
P/E
35.8×
Fwd P/E
35.7×
Dividend yield
0.27%
F-score
5/9
Altman Z
3.84
Beneish M
−2.46
Dividend safety
88/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Thermo Fisher Scientific Inc. 10-Q filed Oct 30, 2026

Fiscal Q3 2026 · Period ended Sep 26, 2026 · Filed · accepted 10:52 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 31, 2026: 6 added · 2 removed · 27 modified; 4 with only figures updated; 5 moved without change

  1. Modified · Organic Revenue Growth

    During the secondthird quarter of 2026, customer activity continued to strengthen remained strong across our end markets. Revenue growth was very strong in the pharma and biotech market, with performance driven by strengthening as underlying market conditions continued to strengthen. Revenues in the academic and government market grew, and growthwere flat. Revenue in the industrial and applied market was very strong, both driven by customer demand for our innovative high-end instruments. Revenue to customers in the diagnostics and healthcare market was also stronggrew slightly. During the secondthird quarter of 2026, sales increased across all major geographies. Revenue growth was strong in North America and Europe and very strong in Asia-Pacific, including China. Contributions to organic revenue during the secondthird quarter of 2026 were led by the Laboratory Products and Biopharma Services segment and the Analytical Instruments segment.

34 more changes in this Item, word by word, in Powerpack.